ERYtech Pharma Wins EuropaBio’s Most Innovative European Biotech SME Award 2014
LYON, France--(BUSINESS WIRE)--Regulatory News:ERYTECH (Paris:ERYP)(Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, won EuropaBio’s Most Innovative European Biotech SME Award 2014.
The award was presented to ERYTECH at a ceremony in Brussels yesterday. It recognizes ERYTECH’s pioneering role in developing an innovative concept to starve cancer cells in specific nutrients and its clinical achievements. The company’s novel breakthrough technology consists in encapsulating therapeutic compounds into red blood cells. It has broad application potential and strong IP protection. Solid proof of concept has been demonstrated in three clinical trials in the treatment of acute lymphoblastic leukemia. Positive Phase III results were announced some days ago.
Help employers find you! Check out all the jobs and post your resume.
The award was presented to ERYTECH at a ceremony in Brussels yesterday. It recognizes ERYTECH’s pioneering role in developing an innovative concept to starve cancer cells in specific nutrients and its clinical achievements. The company’s novel breakthrough technology consists in encapsulating therapeutic compounds into red blood cells. It has broad application potential and strong IP protection. Solid proof of concept has been demonstrated in three clinical trials in the treatment of acute lymphoblastic leukemia. Positive Phase III results were announced some days ago.
Help employers find you! Check out all the jobs and post your resume.